Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could an HIV drug protect new lungs after transplant?

NCT ID NCT06853223

Recruiting now Disease control Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated Jun 13, 2026 · Updated 20 times

Summary

This study tests whether Maraviroc, a drug already approved for HIV, can prevent a serious lung injury called primary graft dysfunction (PGD) after a lung transplant. PGD is a major cause of death in the first year after transplant, and there are no approved treatments for it. About 120 adults getting a double lung transplant will receive either Maraviroc or a placebo for 3 days after surgery. Researchers will compare how many develop severe PGD and how well they recover.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NATURAL KILLER CELL MEDIATED IMMUNITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE LUNG INJURY(ALI) LUNG TRANSPLANTATION LUNG TRANSPLANTATION NATURAL KILLER CELL MEDIATED IMMUNITY PRIMARY GRAFT DYSFUNCTION